| Dr Thomas Nylk, MD | |
|
2385 E Prater Way, Suite 302, Sparks, NV 89434-9629 | |
| (775) 356-4514 | |
| (775) 356-4991 |
| Full Name | Dr Thomas Nylk |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 32 Years |
| Location | 2385 E Prater Way, Sparks, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700869708 | NPI | - | NPPES |
| A89193 | Other | CA | MEDICAL LICENSE |
| 11762408 | Other | CAQH | |
| 12300 | Other | NV | MEDICAL LICENSE |
| 1700869708 | Other | NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | A89193 (California) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 12300 (Nevada) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northern Nevada Medical Center | Sparks, NV | Hospital |
| Northern Inyo Hospital | Bishop, CA | Hospital |
| Renown Regional Medical Center | Reno, NV | Hospital |
| Banner Lassen Medical Center | Susanville, CA | Hospital |
| Entity Name | Banner Lassen Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538197231 PECOS PAC ID: 2961312640 Enrollment ID: O20040126000635 |
News Archive
IRIDEX Corporation today announced that it has added a novel intra-ocular pressure (IOP) monitoring device called a tonometer to its suite of commercial products for the global glaucoma market. The new device comes to IRIDEX through a distribution agreement with Icare Finland Plc, a subsidiary of the Revenio Group Corporation, the creator of the tonometer.
Patients with a very high blood pressure reading in the absence of other symptoms are highly unlikely to have a major adverse cardiovascular event within the next 6 months, researchers report.
Medical professional liability insurance specialist MMIC Group has expanded its insurance services to the growing population of long term care providers.
Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the launch of Epilepsy & Behavior Case Reports a new, online-only, Open Access journal devoted to the rapid publication of case reports on the behavioral aspects of seizures and epilepsy. As a sister journal to Epilepsy & Behavior, case reports published in the new journal will benefit from wide exposure and cross-promotion of the two titles.
› Verified 6 days ago
| Entity Name | Northern Nevada Cardiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225464548 PECOS PAC ID: 5294965703 Enrollment ID: O20140303000353 |
News Archive
IRIDEX Corporation today announced that it has added a novel intra-ocular pressure (IOP) monitoring device called a tonometer to its suite of commercial products for the global glaucoma market. The new device comes to IRIDEX through a distribution agreement with Icare Finland Plc, a subsidiary of the Revenio Group Corporation, the creator of the tonometer.
Patients with a very high blood pressure reading in the absence of other symptoms are highly unlikely to have a major adverse cardiovascular event within the next 6 months, researchers report.
Medical professional liability insurance specialist MMIC Group has expanded its insurance services to the growing population of long term care providers.
Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the launch of Epilepsy & Behavior Case Reports a new, online-only, Open Access journal devoted to the rapid publication of case reports on the behavioral aspects of seizures and epilepsy. As a sister journal to Epilepsy & Behavior, case reports published in the new journal will benefit from wide exposure and cross-promotion of the two titles.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Nylk, MD Po Box 3046, Malvern, PA 19355-0746 Ph: (775) 356-4514 | Dr Thomas Nylk, MD 2385 E Prater Way, Suite 302, Sparks, NV 89434-9629 Ph: (775) 356-4514 |
News Archive
IRIDEX Corporation today announced that it has added a novel intra-ocular pressure (IOP) monitoring device called a tonometer to its suite of commercial products for the global glaucoma market. The new device comes to IRIDEX through a distribution agreement with Icare Finland Plc, a subsidiary of the Revenio Group Corporation, the creator of the tonometer.
Patients with a very high blood pressure reading in the absence of other symptoms are highly unlikely to have a major adverse cardiovascular event within the next 6 months, researchers report.
Medical professional liability insurance specialist MMIC Group has expanded its insurance services to the growing population of long term care providers.
Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the launch of Epilepsy & Behavior Case Reports a new, online-only, Open Access journal devoted to the rapid publication of case reports on the behavioral aspects of seizures and epilepsy. As a sister journal to Epilepsy & Behavior, case reports published in the new journal will benefit from wide exposure and cross-promotion of the two titles.
› Verified 6 days ago
Joseph Jay Teichgraeber, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5975 S Los Altos Pkwy, Suite 100, Sparks, NV 89436 Phone: 775-352-3080 Fax: 775-327-4121 | |
Thomas Nicholas Truong, D.O Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2385 E Prater Way, Suite 302, Sparks, NV 89434 Phone: 775-356-4514 Fax: 775-356-4991 | |
Lynda L Molloy, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2375 E. Prater Way, Sparks, NV 89434 Phone: 775-352-5301 Fax: 775-352-5303 | |
Vijaya Veena Bayya, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 2345 E Prater Way, Suite 104, Sparks, NV 89434 Phone: 775-352-5300 Fax: 775-356-5590 | |
Dr. Ayodele Okunola, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2375 E Prater Way, Sparks, NV 89434 Phone: 775-352-5301 Fax: 775-352-5303 | |
Dr. Kosta M. Arger, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2385 E Prater Way Ste 302, Sparks, NV 89434 Phone: 775-356-4514 Fax: 775-356-4991 | |
Tim Nguyen, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1525 Los Altos Pkwy, Sparks, NV 89436 Phone: 775-982-5000 Fax: 775-982-3900 |